Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Composition of gensenoside Rg1 and ferulic acid for preventing and treating cardiac and cerebral vascular diseases and diabetes and its application

A technology of cardiovascular and cerebrovascular diseases and ginsenosides, which is applied in the field of biologically active compositions, medicines and foods, and can solve problems such as complex ingredients, unrefined formulas, and difficult quality control

Inactive Publication Date: 2005-05-18
YUNNAN WUXIN IND
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although traditional medicine has some compound prescriptions (such as compound salvia miltiorrhiza, etc.) for the prevention and treatment of cardiovascular and cerebrovascular diseases and diabetes, their components are complex, the relationship between the formulas is unclear, the prescriptions are not refined, and the quality is difficult to control.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] Example 1: Compound Ginsenoside Rg1 and Ferulic Acid Jiangxuezhi Granules

[0095] formula:

[0096] Ginsenoside Rg1 95g

[0097] Ferulic Acid 5g

[0098] Sucrose 3000g

[0099] Dextrin 400g

[0100] Proper amount of ethanol

[0101] Granulate according to the common granulation method, and pack into 1000 bags (about 3.5g per bag). Take one bag each time, 1-2 times a day.

Embodiment 2

[0102] Embodiment 2: compound ginsenoside Rg1 and ferulic acid capsules

[0103] formula:

[0104] Ginsenoside Rg1 75g

[0105] Ferulic Acid 25g

[0106] Polyethylene Glycol-400 300g

[0107] According to the preparation method of ordinary capsules, the content of each capsule weighs about 400mg, and 1000 capsules can be obtained.

[0108] 35 patients with myocardial infarction were treated with this product. After 28 days of treatment, more than 95% of the patients were relieved to varying degrees, of which 55% were markedly effective and 40% were improved. The total effective rate of electrocardiogram is 66.4%.

Embodiment 3

[0109] Example 3: Compound Ginsenoside Rg1 and Ferulic Acid Frozen Powder Injection

[0110] formula:

[0111] Ginsenoside Rg1 125g

[0112] Ferulic Acid 75g

[0113] Mannitol 100g

[0114] Prepare the freeze-dried preparation according to the ordinary freeze-drying method, and can make 1000 sticks of 200 mg compound ginsenoside Rg1 and ferulic acid freeze-dried powder injection.

[0115] Pharmacodynamic test of compound ginsenoside Rg1 and ferulic acid powder injection: Equal volume of normal saline (NS), compound Danshen injection and compound ginsenoside Rg1 and ferulic acid powder injection were used as negative control group, positive control group and experimental group respectively. group, compound ginsenoside Rg1 and ferulic acid powder injection antagonized pituitary hormone-induced reduction of isolated guinea pig heart coronary flow (p<0.01) in a dose-effect relationship, better than compound Danshen group. In an anesthetized rat model of myocardial ischemia wit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a composition of ginsenoside Rg1 and ferulic acid for preventing and treating cardiovascular and cerebrovascular diseases and diabetes and its application. Although ginsenoside and ferulic acid have certain curative effects on cardiovascular and cerebrovascular diseases and diabetic complications, their comprehensive curative effect needs to be improved. Although traditional medicine has some compound prescriptions (such as compound salvia miltiorrhiza, etc.) that are used to prevent and treat cardiovascular and cerebrovascular diseases and diabetes, their components are complex, the relationship between the formulas is unclear, the prescriptions are not refined, and the quality is difficult to control. The product of the invention is composed of the following raw materials in weight percentage: ginsenoside Rg1: 5%-95%, ferulic acid 5%-95%. The combined use of ginsenoside Rg1 and ferulic acid can cooperate with each other to regulate blood function, treat or improve diseases or dysfunctions caused by blood system or cardiovascular and cerebrovascular changes or blood sugar changes. The purpose of the product is to prepare pharmaceutically or food-acceptable preparations with an appropriate amount of medicinal or edible excipients. The positive effect is that the comprehensive curative effect is good, the prescription is concise, and the quality is easy to control.

Description

technical field [0001] The invention relates to a composition for preventing and treating cardiovascular and cerebrovascular diseases and diabetes, in particular to a biologically active composition composed of ginsenoside Rg1 and ferulic acid, and the use of the composition in the preparation of medicines and foods use. Background technique [0002] Research data confirm that ginsenoside Rg1 can effectively improve the hemodynamics of blood circulation, reduce blood viscosity, reduce blood fat, and improve beauty. It is a commonly used natural extract and has pharmaceutical standards. Ferulic acid is one of the main components of Angelica and Chuanxiong. Ferulic acid has the functions of anti-oxidation, inhibition of platelet aggregation, anti-thrombosis, lowering blood fat, anti-myocardial ischemia, improvement of microcirculation, and beauty. Although ginsenoside Rg1 and ferulic acid have certain curative effects on cardiovascular and cerebrovascular diseases and diabet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/704A61P3/10A61P9/10
Inventor 余树华
Owner YUNNAN WUXIN IND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products